
EXHIBIT 24

Summary under Fed. R. Evid. 1006: Theriva's shares outstanding, 2017–2026, and timeline of the events alleged

Nejmeh v. Theriva Biologics, Inc., No. 3:26-cv-00705-ART-CSD (D. Nev.)
Cited in the First Amended Verified Complaint, paragraph(s) 1, 2

Source
Prepared at Plaintiff's direction from Theriva's filings with the SEC and the other sources named in each row. Share counts are those on the cover page of each Theriva Form 10-Q and Form 10-K (SEC structured data, "EntityCommonStockSharesOutstanding"), the counts stated in the reverse split Forms 8-K, and the record-date count in the November 10, 2025 proxy statement. The right-hand column gives the paragraph of the First Amended Verified Complaint where each event is alleged. The underlying documents are public.

Theriva's shares outstanding, 2017–2026



Shares of Theriva common stock outstanding (logarithmic scale). Red dashed lines: reverse stock splits.

Data points: 2017-02-28: 117,541,978 (10-K cover, Acc. 0001144204-17-012545); 2017-05-02: 121,894,034 (10-Q cover, Acc. 0001144204-17-024592); 2017-07-31: 128,247,070 (10-Q cover, Acc. 0001144204-17-040110); 2017-10-31: 128,566,883 (10-Q cover, Acc. 0001144204-17-055540); 2018-02-21: 128,566,886 (10-K cover, Acc. 0001144204-18-010286); 2018-05-06: 128,566,866 (10-Q cover, Acc. 0001144204-18-026171); 2018-08-06: 132,969,743 (10-Q cover, Acc. 0001144204-18-042887); 2018-08-10: 3,799,136 (8-K 0001144204-18-043710); 2018-11-07: 13,483,976 (10-Q cover, Acc. 0001144204-18-058414); 2019-02-26: 15,484,411 (10-K cover, Acc. 0001144204-19-010592); 2019-05-08: 16,483,821 (10-Q cover, Acc. 0001144204-19-024539); 2019-08-06: 16,806,430 (10-Q cover, Acc. 0001144204-19-038590); 2019-10-31: 16,806,430 (10-Q cover, Acc. 0001104659-19-059538); 2020-02-18: 16,956,865 (10-K cover, Acc. 0001104659-20-023415); 2020-05-01: 18,263,543 (10-Q cover, Acc. 0001104659-20-056927); 2020-08-03: 19,440,346 (10-Q cover, Acc. 0001104659-20-091503); 2020-11-06: 19,993,390 (10-Q cover, Acc. 0001104659-20-123646); 2021-03-03: 129,654,575 (10-K cover, Acc. 0001104659-21-032150); 2021-05-04: 132,042,538 (10-Q cover, Acc. 0001104659-21-061771); 2021-08-03: 132,042,538 (10-Q cover, Acc. 0001104659-21-100800); 2021-11-03: 132,042,538 (10-Q cover, Acc. 0001104659-21-133722); 2022-03-16: 158,437,840 (10-K cover, Acc. 0001410578-22-000405); 2022-05-13: 158,437,840 (10-Q cover, Acc. 0001410578-22-001679); 2022-07-25: 15,843,784 (8-K 0001104659-22-082251); 2022-08-10: 15,844,061 (10-Q cover, Acc. 0001410578-22-002238); 2022-11-09: 15,844,061 (10-Q cover, Acc. 0001410578-22-003167); 2023-03-28: 15,124,061 (10-K cover, Acc. 0001410578-23-000428); 2023-05-10: 15,124,061 (10-Q cover, Acc. 0001410578-23-000987); 2023-08-02: 17,042,765 (10-Q cover, Acc. 0001410578-23-001584); 2023-11-08: 17,042,765 (10-Q cover, Acc. 0001410578-23-002348); 2024-03-21: 17,148,049 (10-K cover, Acc. 0001410578-24-000293); 2024-05-03: 17,277,371 (10-Q cover, Acc. 0001410578-24-000601); 2024-08-09: 25,131,230 (10-Q cover, Acc. 0001410578-24-001342); 2024-08-26: 1,005,249 (8-K 0001104659-24-092644); 2024-11-08: 2,782,449 (10-Q cover, Acc. 0001410578-24-001850); 2025-03-04: 2,782,449 (10-K cover, Acc. 0001410578-25-000285); 2025-05-12: 8,186,989 (10-Q cover, Acc. 0001410578-25-001242); 2025-08-07: 9,597,952 (10-Q cover, Acc. 0001410578-25-001654); 2025-10-30: 33,739,643 (DEF 14A 0001104659-25-109200 (record date)); 2025-11-07: 33,739,643 (10-Q cover, Acc. 0001104659-25-109828); 2026-03-10: 45,892,668 (10-K cover, Acc. 0001104659-26-026767); 2026-05-01: 45,892,668 (10-Q cover, Acc. 0001104659-26-055689); 2026-08-07: 45,892,668 (10-Q cover, Acc. 0001104659-26-093786).

Timeline of events alleged in the First Amended Verified Complaint

Date	What happened	Source	FAC ¶
Apr. 25, 2007	1-for-3 reverse stock split (Pipex Pharmaceuticals).	10-K filed Mar. 31, 2008, note (C)	23
Aug. 10, 2018	1-for-35 reverse split: 132,969,743 shares become 3,799,136.	8-K 0001144204-18-043710	23
Aug. 17 & 24, 2018	finviz.com shows 141.96M and 127.16M shares; market cap $362.00M and $347.15M.	Internet Archive (Ex. 22)	31
Oct. 10-15, 2018	A.G.P. underwritten offering: units at $1.15, Series B preferred convertible into 13,672,173 shares, warrants; about 34.2M potential new shares on 3.8M.	8-K 0001144204-18-053807	33
Jan. 27, 2021	Series A preferred (sold to MSD in 2017) conversion price cut from $18.90 to $1.50; the holder converts into 8,465,154 shares (Jan. 29 - Feb. 9).	8-Ks 0001104659-21-008261, -009459, -014306, -016924	17
July 25, 2022	1-for-10 reverse split: 158,437,840 shares become 15,843,784.	8-K 0001104659-22-082251	23
July 28-29, 2022	MSD (reports jointly with Michael S. Dell) buys Series C/D preferred for about $3M; Series D carries 2,000,000,000 votes; A.G.P. fee $175,000.	8-K 0001104659-22-084301 (Ex. 13)	1, 18-19
Aug. 10, 2022	Yahoo Finance shows market cap $187.501M (about 132M shares) when Theriva had about 15.84M.	Internet Archive (Ex. 22)	31
Sept. 30, 2022	Authorized shares raised 20M to 350M. Common FOR: 5,517,109 (34.8%); passes only with Series D votes.	8-K 0001104659-22-105229 (Ex. 13)	20
Oct. 2, 2023	Shallcross tells Plaintiff Theriva cannot increase authorized shares after a reverse split.	Plaintiff	21
Aug. 26, 2024	1-for-25 reverse split by the board alone: 25,131,230 shares become 1,005,249; authorized cut to 14M.	8-Ks 0001104659-24-090522, -092644	22, 34
Aug. 30, 2024	26,144,100 shares trade (about 26 times the company); high $7.15. No press release, no 8-K.	Yahoo data (Ex. 23)	34
Sept. 26-27, 2024	A.G.P. offering at $1.75 with $2.00 warrants; stock closes $1.49.	8-K 0001104659-24-103813 (Ex. 23)	34
Oct. 31, 2024	Stockholders approve authorized shares 14M to 350M.	8-K 0001104659-24-113480	35
Apr. 29, 2025	Board grants options at $1.4144 (Shallcross 190,000).	Forms 4	53
May 7, 2025	VIRAGE results and A.G.P. offering priced at $1.10 the same day; stock $1.36 to $0.81; 2,803,100 shares sold short.	8-Ks; FINRA short sale file; SEC fails data (Ex. 17)	50-52
Oct. 15, 2025	196.6 million shares trade; close $0.84.	424B5; trading data	61
Oct. 16-17, 2025	Warrants repriced to $0.54; 16,184,560 New Warrants (2 for 1); value $5.9M for $4.4M cash. A.G.P. 7% fee.	8-K (Ex. 4); 10-Q (Ex. 5)	55-56
Oct. 1 - Nov. 12, 2025	A.G.P. sells 15,342,601 new shares through the at-the-market program.	10-Q (Ex. 6); 8-K	60
Oct. 24, 2025	More than 540M shares trade. 2:31 p.m.: "no material development." Yahoo/MarketWatch show stale counts.	Ex. 15, 16, 18	61-62, 64
Oct. 30, 2025	Record date for the New Warrant vote: 33,739,643 shares (from 10,304,762 on Sept. 30).	DEF 14A 0001104659-25-109200	63
Nov. 10, 2025	Proxy mailed. Gryga 13G: 739,211 shares as "7.7%" (old count 9,597,952).	13G 0002096075-25-000001	64
Dec. 15, 2025	Special meeting (Rockville) fails: no quorum. Plaintiff attends. Shallcross says the meeting could adjourn to Dec. 22. After the	ECF 15-1; ECF 4-3 at 10, 184	67-69

	meeting, Theriva's counsel tells Plaintiff by phone: "You don't really want to have the meeting on December 22." No Dec. 22 meeting is held.		
Jan. 5, 2026	Board grants options at $0.241 (Shallcross 475,000).	Forms 4	62
Feb. 11, Apr. 9, June 5, 2026	Three more meetings, in person only in Spain, fail.	ECF 15-1	66-67
Feb. 17-18, 2026	SYN-020 licensed to Rasayana for $300,000 upfront.	8-K 0001104659-26-016792 (Ex. 10)	44-45
Q1 2026	10,204,319 more shares sold through the at-the-market program.	10-Q (Ex. 5)	87
Aug. 3, 2026	Annual meeting (Spain): quorum made by 10,823,826 broker shares; New Warrants approved 3,665,312 to 2,267,592.	8-K 0001104659-26-090064 (Ex. 8)	77-80
Aug. 10, 2026	Shallcross contract rewritten: signing a reverse-merger agreement now triggers his change-in-control benefits.	10-Q Ex. 10.1 (Ex. 19)	89
Oct. 9, 2026	Proxy seeks 500,000,000 authorized shares "not adjusted" for a reverse split; meeting in Spain; no recording.	PRE 14A 0001104659-26-115074 (Ex. 9)	84-86